Showing Results for
- Academic Journals (14)
Search Results
- 14
Academic Journals
- 14
-
From:Future Oncology (Vol. 11, Issue 20) Peer-ReviewedAuthor(s): Srdan Verstovsek [*] aff1 , Rami S Komrokji aff2 KEYWORDS efficacy; FLT3; JAK2; myelofibrosis; pacritinib; safety; tyrosine kinase inhibitor Epidemiology & pathobiology of myelofibrosis...
-
From:Future Oncology (Vol. 11, Issue 20) Peer-ReviewedAuthor(s): Carsten Stephan [*] aff1 aff2 , Klaus Jung aff1 aff2 , Bernhard Ralla aff1 KEYWORDS AUC; cancer; ETS ; free PSA; kallikreins; PCA3 ; phi; prostate; prostate biopsy; prostate volume; PSA; PSA...
-
From:Future Oncology (Vol. 11, Issue 20) Peer-ReviewedAuthor(s): Bekir Hacioglu aff1 , Serkan Akin aff1 , Taner Babacan aff1 , Ali R Sever aff2 , Kadri Altundag [*] aff1 KEYWORDS breast; cancer; complete remission; HER2 positive; long term; maintenance therapy;...
-
From:Future Oncology (Vol. 11, Issue 20) Peer-ReviewedAuthor(s): Guy Jerusalem [*] aff1 , Marie Moonen aff2 , Pierre Freres aff1 , Patrizio Lancellotti aff2 KEYWORDS anthracyclines; breast cancer; cardiac toxicity; cardio-oncology; monitoring; trastuzumab The...
-
From:Future Oncology (Vol. 11, Issue 20) Peer-ReviewedAuthor(s): Giorgio Gandaglia [*] aff1 aff2 , Francesco Montorsi aff1 , Pierre I Karakiewicz aff2 , Maxine Sun aff2 KEYWORDS biochemical recurrence; cancer-specific survival; erectile dysfunction; healthcare...
-
From:Future Oncology (Vol. 11, Issue 20) Peer-ReviewedAuthor(s): Jack A Schalken [*] aff1 , Gemma Westcott aff2 KEYWORDS biomarkers; early diagnosis; emerging agents; multiparametric MRI; PARP; prostate cancer The early diagnosis of prostate cancer and the...
-
From:Future Oncology (Vol. 11, Issue 20) Peer-ReviewedAuthor(s): Navneet Momi aff1 , Vadim Backman aff2 , Charles B Brendler aff3 , Hemant K Roy [*] aff1 KEYWORDS biomarker; miRNAs; nanocytology; overdiagnosis; prostate cancer; PWS Prostate cancer Despite being...
-
From:Future Oncology (Vol. 11, Issue 20) Peer-ReviewedMantle cell lymphoma (MCL) is a hematological malignancy with unfavorable prognosis. Bortezomib, a potent, selective and reversible inhibitor of the 26S proteasome, was shown to be active in MCL and is currently...
-
From:Future Oncology (Vol. 11, Issue 20) Peer-ReviewedAuthor(s): Arran K Turnbull [*] aff1 KEYWORDS breast cancer; cancer; personalized medicine What is personalized medicine? In an ideal world, our vision for personalized medicine involves measurement of some key...
-
From:Future Oncology (Vol. 11, Issue 20) Peer-ReviewedAuthor(s): Eduard Vrdoljak [*] aff1 , Martin Gore aff2 , Sophie Leyman aff3 , Cezary Szczylik aff4 , Galina Kharkevich aff5 , Patrick Schöffski aff6 , Laszlo Torday aff7 , Josef Mardiak aff8 , Ke Zhang aff9 , Peter...
-
From:Future Oncology (Vol. 11, Issue 20) Peer-ReviewedAuthor(s): Ya-Li Cui [*] aff1 , Xuemei Wang aff2 , Xiao-Feng Li [**] aff3 KEYWORDS 18 F-fluoromisonidazole; change in hypoxia; hypoxia; non-small-cell lung cancer; tumor microenvironment Lung cancer is...
-
From:Future Oncology (Vol. 11, Issue 20) Peer-ReviewedAuthor(s): Andreas G Wibmer [*] aff1 , Hebert Alberto Vargas aff1 , Hedvig Hricak aff1 KEYWORDS cancer detection; cancer recurrence; cancer staging; MRI; prostate cancer; risk assessment; whole-body MRI...
-
From:Future Oncology (Vol. 11, Issue 20) Peer-ReviewedAuthor(s): Colin Watts [*] aff1 , Sara GM Piccirillo aff2 In the Editorial by Colin Watts, titled 'Clonal diversity in glioblastoma: is it clinically relevant?', which appeared in the June 2015 issue of Future...
-
From:Future Oncology (Vol. 11, Issue 20) Peer-ReviewedAuthor(s): Amanda R Hathaway aff1 , Mary Katherine Baker aff1 , Guru Sonpavde [*] aff1 KEYWORDS androgen inhibitors; emerging agents; immunotherapy; mCRPC; metastatic castration-resistant prostate cancer...